XCUR logo

EXICURE INC

XCURNASDAQ
🏆 #5072 by market capEarnings Nov 12US Equity
$1.25▲ $0.02 (+1.63%)
After hours · at close
🔔
Track XCUR
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.6%
7d▲ 1.6%
14d▼ 7.1%
30d▼ 6.4%
ytd▼ 77.5%
1y▼ 67.5%
🏦Market Cap
$8M
Small Cap
📈Revenue Growth (YoY)
-100.0%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
72
Fair

Trading Snapshot

Day Range
$1.23 – $1.27
52-Week Range
$1.05 – $9.48
Volume
$4.65B
Avg Volume
$4.66B
Shares Outstanding
6.4M
Next Earnings
Dec 12, 2026

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$314,770
P/E Ratio
-0.9
P/S Ratio
0.0x
EPS (TTM)
$-1.30
Dividend Yield
0.00%
Dilution (1yr)
+4.5%

Why Investors Own XCUR

  • ✓High-growth profile — revenue up +12.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 31% gross margin and 16% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

XCUR logo

EXICURE INC

XCUR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +6.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$10M▼ −17.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$9M▲ +194.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
6.3M▲ +4.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$4M▼ −$3M YoY
StockOtter · stockotter.space

About EXICURE INC

Exicure, Inc. is a biotechnology firm that utilizes its unique spherical nucleic acid (SNA) platform to create therapies for neurological conditions and hair loss. Its primary experimental candidate, SCN9A, is currently undergoing preclinical evaluation for addressing neuropathic and chronic pain. The company has entered into a strategic partnership with AbbVie Inc. to advance SNA-based solutions for various hair loss conditions, under a collaboration, option, and license agreement. Additionally, a separate collaborative effort with Ipsen S.A. aims to investigate, develop, and commercialize novel spherical nucleic acids targeting Huntington's disease and Angelman syndrome. Established in 2011, Exicure's corporate base is located in Chicago, Illinois.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$1.64
▲ +31.6% Upside
High Target$1.80
Low Target$1.23
Based on 16 analysts

Latest News & Updates

🚀
Barron’s·2h ago

EXICURE INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift XCUR price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

EXICURE INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.